Skip to main content

CareDx to Buy Transplant Dx Firm ImmuMetrix

NEW YORK (GenomeWeb) – CareDx, formerly called XDx, said late Wednesday that it has reached an agreement to acquire transplant diagnostic company ImmuMetrix for an undisclosed amount.

A development stage firm based in Palo Alto, Calif., ImmuMetrix was co-founded by Stephen Quake and Dan Seligson and has R&D programs and intellectual property in cell-free DNA, CareDx said. It added that ImmuMetrix has "pioneered contributions" in fields including single-cell gene expression, genome sequencing, non-invasive tests for heart transplant rejection, and approaches to sequencing and analyzing an individual's immune system.

According to ImmuMetrix's website, the company has an R&D program directed at cancer, transplantation, allergies, vaccine, autoimmunity, and asthma, and it has developed assays for immune repertoire profiling.

"We believe that this acquisition will further strengthen our position in organ transplant surveillance for both our current indication in heart with AlloMap and with other organs in our pipeline," CareDx President and CEO Peter Maag said in a statement.

AlloMap measures the expression levels of 20 genes from a blood sample and provides clinicians a tool for evaluating a patient's risk for a heart transplant rejection. The company launched the test in 2005, and the US Food and Drug Administration approved the test three years later.

"The combination of innovative cell-free DNA technology from ImmuMetrix, with the strong commercial channel provided by CareDx, will result in a new generation of diagnostic products to improve the care and treatment of transplant patients," Stephen Fodor, a board member of ImmuMetrix, said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.